SHIRE PLC: Results of the 2014 Annual General Meeting

Results of the 2014 Annual General Meeting 
April 29, 2014 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") announces
that at its Annual General Meeting held at The Merrion Hotel, Upper Merrion
Street, Dublin 2, Ireland at 1.30 pm today, all resolutions contained in the
notice of meeting were decided by poll vote. The results of the poll are as
follows: 
Resolution                       For        %     Against     %     Votes    
Withheld 


                             (including                            cast as
                            discretionary                           a % of
                               votes)                              relevant
                                                                    shares


                                                               in issue
Ordinary Resolutions 
1. To receive the Company's 400,965,756   98.95% 4,249,303  1.05%   68.80%  
1,472,435
Annual Report and Accounts
for the year ended December
31, 2013. 
2. To approve the           391,218,791   96.97% 12,224,728 3.03%   68.50%  
3,243,975
Directors' Remuneration
Report. 
3. To approve the           374,694,890   94.71% 20,926,142 5.29%   67.17%  
11,066,462
Directors' Remuneration
Policy. 
4. To elect Dominic         404,467,447   99.82% 716,284    0.18%   68.80%  
1,503,763
Blakemore as a Director. 
5. To re-elect William      400,680,783   98.89% 4,510,166  1.11%   68.80%  
1,496,545
Burns as a Director. 
6. To re-elect Dr. Steven   404,565,517   99.84% 628,936    0.16%   68.80%  
1,493,041
Gillis as a Director. 
7. To re-elect Dr. David    404,559,335   99.84% 630,570    0.16%   68.80%  
1,497,589
Ginsburg as a Director. 
8. To re-elect David        398,241,506   98.74% 5,089,868  1.26%   68.48%  
3,356,120
Kappler as a Director. 
9. To re-elect Susan Kilsby 391,916,029   96.72% 13,277,757 3.28%   68.80%  
1,493,708
as a Director. 
10. To re-elect Anne Minto  400,967,152   99.45% 2,206,094  0.55%   68.45%  
3,514,248
as a Director. 
11. To re-elect Dr.         404,554,602   99.84% 632,552    0.16%   68.80%  
1,500,340
Flemming Ornskov as a
Director. 
12. To elect David Stout as 403,130,381   99.49% 2,060,469  0.51%   68.80%  
1,496,644
a Director. 
13. To re-appoint Deloitte  401,119,071   98.99% 4,096,849  1.01%   68.80%  
1,471,574
LLP as the Company's
Auditor. 
14. To authorize the Audit, 402,286,337   99.93% 284,166    0.07%   68.35%  
4,116,991
Compliance & Risk Committee
to determine the
remuneration of the
Auditor. 
15. To approve the increase 404,516,894   99.86% 553,107    0.14%   68.78%  
1,617,493
in the Company's borrowing
powers. 
16. To authorize the        373,096,915   92.54% 30,095,078 7.46%   68.46%  
3,495,501
allotment of shares.
Special Resolutions 
17. To authorize the        397,955,909   98.47% 6,202,843  1.53%   68.62%  
2,528,742
disapp99.95lication of
pre-emption rights. 
18. To authorize market     404,995,809   99.95% 195,629    0.05%   68.80%  
1,496,056
purchases. 
19. To approve the notice   342,512,195   84.53% 62,696,077 15.47%  68.80%  
1,479,222
period for general
meetings. 
As at the record date, April 27, 2014, there were 588,965,802 ordinary shares
in issue (excluding shares held in treasury). Shareholders are entitled to one
vote per share. A vote "withheld" is not a vote in law and is not counted in
the calculation of the proportion of votes validly cast. 
In accordance with Listing Rule 9.6.2R copies of the relevant resolutions
passed at the meeting have been submitted to the National Storage Mechanism
and will be available for viewing shortly at: www.morningstar.co.uk/uk/nsm. 
Tony Guthrie
Deputy Company Secretary 
For further information please contact: 
Investor Relations
Jeff Poulton                  jpoulton@shire.com   +1 781 482 0945
Eric Rojas                    erojas@shire.com     +1 781 482 0999
Sarah Elton-Farr              seltonfarr@shire.com +44 1256 894157 
Media
Jessica Mann                  jmann@shire.com      +44 1256 894 280 
NOTES TO EDITORS 
Shire enables people with life-altering conditions to lead better lives. 
Our strategy is to focus on developing and marketing innovative specialty
medicines to meet significant unmet patient needs. 
We provide treatments in Neuroscience, Rare Diseases, Gastrointestinal and
Internal Medicine and we are developing treatments for symptomatic conditions
treated by specialist physicians in other targeted therapeutic areas. 
www.shire.com 
END 
-0- Apr/29/2014 14:40 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.